(PFE) Pfizer - Ratings and Ratios
Vaccines, Antivirals, Oncology, Immunology, Sterile-Injectables
PFE EPS (Earnings per Share)
PFE Revenue
Description: PFE Pfizer
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells a broad portfolio of biopharmaceutical products worldwide, spanning small-molecule drugs, biologics, vaccines, and biosimilars across multiple therapeutic areas.
Key therapeutic segments include cardiovascular and migraine treatments (e.g., Eliquis, Nurtec ODT), infectious-disease vaccines (Prevnar, Abrysvo), COVID-19 prevention and therapy (Comirnaty, Paxlovid), and specialty medicines for chronic immune, inflammatory, hematologic, and endocrine disorders (Xeljanz, Enbrel, Oxbryta, Ibrance, etc.). The company also operates a contract-manufacturing business and serves a diverse customer base that includes wholesalers, hospitals, pharmacies, and government agencies.
Recent performance metrics (as of Q2 2024) show a revenue run-rate of roughly $14 billion, driven largely by sustained demand for COVID-19 products and a 7 % YoY growth in the vaccine segment, while the biosimilar portfolio contributed a 12 % increase in margin expansion. A primary sector driver is the aging global population, which underpins rising demand for chronic-disease therapies, and a secondary driver is the ongoing shift toward mRNA and antiviral platforms, where Pfizer’s partnership with BioNTech positions it to capture a growing market share.
For a deeper, data-rich analysis of Pfizer’s valuation dynamics and scenario modeling, you may find additional insights on ValueRay helpful.
PFE Stock Overview
| Market Cap in USD | 143,503m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2012-08-13 |
PFE Stock Ratings
| Growth Rating | -47.7% |
| Fundamental | 60.7% |
| Dividend Rating | 71.2% |
| Return 12m vs S&P 500 | -22.4% |
| Analyst Rating | 3.56 of 5 |
PFE Dividends
| Dividend Yield 12m | 6.98% |
| Yield on Cost 5y | 6.04% |
| Annual Growth 5y | 3.89% |
| Payout Consistency | 97.9% |
| Payout Ratio | 54.8% |
PFE Growth Ratios
| Growth Correlation 3m | 8.2% |
| Growth Correlation 12m | -28.3% |
| Growth Correlation 5y | -69.2% |
| CAGR 5y | -13.81% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.25 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.36 |
| Sharpe Ratio 12m | -0.53 |
| Alpha | -20.59 |
| Beta | 0.465 |
| Volatility | 30.75% |
| Current Volume | 39808.7k |
| Average Volume 20d | 47744.2k |
| Stop Loss | 23.7 (-3.3%) |
| Signal | 0.51 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (10.75b TTM) > 0 and > 6% of Revenue (6% = 3.83b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 3.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.36% (prev -10.66%; Δ 20.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 15.19b > Net Income 10.75b (YES >=105%, WARN >=100%) |
| Net Debt (60.16b) to EBITDA (22.77b) ratio: 2.64 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (5.71b) change vs 12m ago 0.18% (target <= -2.0% for YES) |
| Gross Margin 67.34% (prev 49.11%; Δ 18.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 30.23% (prev 26.01%; Δ 4.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.65 (EBITDA TTM 22.77b / Interest Expense TTM 2.83b) >= 6 (WARN >= 3) |
Altman Z'' 3.54
| (A) 0.03 = (Total Current Assets 43.70b - Total Current Liabilities 37.73b) / Total Assets 206.09b |
| (B) 0.57 = Retained Earnings (Balance) 117.61b / Total Assets 206.09b |
| (C) 0.08 = EBIT TTM 15.99b / Avg Total Assets 211.14b |
| (D) 0.94 = Book Value of Equity 109.65b / Total Liabilities 117.08b |
| Total Rating: 3.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.71
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 6.48% = 3.24 |
| 3. FCF Margin 19.49% = 4.87 |
| 4. Debt/Equity 0.70 = 2.26 |
| 5. Debt/Ebitda 2.64 = -1.21 |
| 6. ROIC - WACC (= 4.26)% = 5.32 |
| 7. RoE 11.96% = 1.00 |
| 8. Rev. Trend -50.93% = -3.82 |
| 9. EPS Trend -29.14% = -1.46 |
What is the price of PFE shares?
Over the past week, the price has changed by -1.09%, over one month by +1.91%, over three months by +1.44% and over the past year by -10.39%.
Is Pfizer a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PFE is around 22.33 USD . This means that PFE is currently overvalued and has a potential downside of -8.89%.
Is PFE a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 15
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the PFE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.9 | 17.7% |
| Analysts Target Price | 28.9 | 17.7% |
| ValueRay Target Price | 24.3 | -1% |
Last update: 2025-10-11 05:03
PFE Fundamental Data Overview
P/E Trailing = 13.3545
P/E Forward = 8.673
P/S = 2.2481
P/B = 1.7359
P/EG = 3.7725
Beta = 0.465
Revenue TTM = 63.83b USD
EBIT TTM = 15.99b USD
EBITDA TTM = 22.77b USD
Long Term Debt = 56.63b USD (from longTermDebt, last quarter)
Short Term Debt = 4.29b USD (from shortTermDebt, last quarter)
Debt = 61.80b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 60.16b USD (from netDebt column, last quarter)
Enterprise Value = 192.05b USD (143.50b + Debt 61.80b - CCE 13.25b)
Interest Coverage Ratio = 5.65 (Ebit TTM 15.99b / Interest Expense TTM 2.83b)
FCF Yield = 6.48% (FCF TTM 12.44b / Enterprise Value 192.05b)
FCF Margin = 19.49% (FCF TTM 12.44b / Revenue TTM 63.83b)
Net Margin = 16.85% (Net Income TTM 10.75b / Revenue TTM 63.83b)
Gross Margin = 67.34% ((Revenue TTM 63.83b - Cost of Revenue TTM 20.85b) / Revenue TTM)
Gross Margin QoQ = 64.29% (prev 71.65%)
Tobins Q-Ratio = 0.93 (Enterprise Value 192.05b / Total Assets 206.09b)
Interest Expense / Debt = 1.06% (Interest Expense 654.0m / Debt 61.80b)
Taxrate = 4.63% (141.0m / 3.04b)
NOPAT = 15.25b (EBIT 15.99b * (1 - 4.63%))
Current Ratio = 1.16 (Total Current Assets 43.70b / Total Current Liabilities 37.73b)
Debt / Equity = 0.70 (Debt 61.80b / totalStockholderEquity, last quarter 88.69b)
Debt / EBITDA = 2.64 (Net Debt 60.16b / EBITDA 22.77b)
Debt / FCF = 4.84 (Net Debt 60.16b / FCF TTM 12.44b)
Total Stockholder Equity = 89.88b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.22% (Net Income 10.75b / Total Assets 206.09b)
RoE = 11.96% (Net Income TTM 10.75b / Total Stockholder Equity 89.88b)
RoCE = 10.91% (EBIT 15.99b / Capital Employed (Equity 89.88b + L.T.Debt 56.63b))
RoIC = 9.96% (NOPAT 15.25b / Invested Capital 153.00b)
WACC = 5.71% (E(143.50b)/V(205.30b) * Re(7.73%) + D(61.80b)/V(205.30b) * Rd(1.06%) * (1-Tc(0.05)))
Discount Rate = 7.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.52%
[DCF Debug] Terminal Value 73.62% ; FCFE base≈9.39b ; Y1≈7.15b ; Y5≈4.40b
Fair Price DCF = 14.55 (DCF Value 82.72b / Shares Outstanding 5.69b; 5y FCF grow -28.32% → 3.0% )
EPS Correlation: -29.14 | EPS CAGR: -36.53% | SUE: 1.30 | # QB: 8
Revenue Correlation: -50.93 | Revenue CAGR: -14.63% | SUE: 0.57 | # QB: 0
Additional Sources for PFE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle